An interesting patient case demonstrating the safe and effective use of venetoclax for relapsed t(11;14) multiple myeloma in parallel with pembrolizumab for advanced non-small cell lung cancer (NSCLC) ‘strongly supports’ further development of venetoclax for this subset of multiple myeloma patients, UK clinicians say. The FDA halted venetoclax trials in myeloma in March 2019 when ...
Case study illustrates potential of venetoclax in MM subgroup
By Jennie James
19 Feb 2020